Clinical application of immunoreactivity of dihydropyrimidine dehydrogenase (DPD) in gastric scirrhous carcinoma treated with S-1, a new DPD inhibitory fluoropyrimidine
Shimizu, T.; Yamada, Y.; Yasui, H.; Shirao, K.; Fukuoka, M.
Anticancer Research 25(4): 2997-3001
2005
ISSN/ISBN: 0250-7005 PMID: 16080558 Document Number: 584735
Background: A highly specific antibody against recombinant human dihydropyrimidine dehydrogenase (DPD) has been developed to immunohistochemically assess DPD expression in tumors. A new oral DPD inhibitory fluoropyrimidine (DIF), S-1, is reportedly effective against gastric scirrhous carcinoma. Patients and Methods: In this study, the relationship between immunoreactivity to DPD in biopsy specimens and the effects of chemotherapy were investigated in 61 patients treated with first-line fluoropyrimidine-based chemotherapy (S-I:DIF, 5-FU:nonDIF) for gastric scirrhous carcinoma. Results: The response rate was significantly higher in patients with DPD-positive tumors than in those with DPD-negative tumors in the S-1 group (45.5%, 10.0% : p < 0.05), as compared to the 5-FU group (0%, 5.6%: p=0.398). According to the median survival time, there was no significant difference between patients with DPD-positive tumors (364 days) and those with DPD-negative tumors (406 days; p=0.626) in either the S-1 group or the 5-FU group (181 days and 256 days, respectively; p=0.543). Conclusion: This study indicates that S-1 may be effective even in gastric scirrhous carcinoma with a high level of DPD activity.